This week, 11 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Pacira Pharmaceuticals, Inc. (PCRX) gets weaker ratings this week as last week’s C drops to a D. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PCRX stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
This is a rough week for Akorn, Inc. (AKRX). The company’s rating falls to D from the previous week’s C. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of AKRX stock.
Intersect ENT Inc (XENT) slips from a C to a D this week. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.
Cempra, Inc. (CEMP) experiences a ratings drop this week, going from last week’s C to a D. Cempra, Inc. manufactures and markets pharmaceutical products. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of CEMP stock.
This week, Flamel Technologies SA Sponsored ADR’s (FLML) rating worsens to a D from the company’s C rating a week ago. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLML stock.
This week, Ocular Therapeutix Inc (OCUL) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCUL stock.
Slipping from a C to a D rating, Egalet Corporation (EGLT) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.
Alcobra Ltd. (ADHD) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADHD stock.
Endocyte, Inc.’s (ECYT) rating weakens this week, dropping to a F versus last week’s D. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in sales growth, operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.
Acura Pharmaceuticals, Inc. (ACUR) earns a D this week, moving down from last week’s grade of C. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
